Regenerative Medicine Applied to Solid Organ Transplantation: Where Do We Stand?

被引:7
|
作者
Orlando, G. [1 ]
Di Cocco, P. [1 ]
D'Angelo, M. [1 ]
Clemente, K. [1 ]
Famulari, A. [1 ]
Pisani, F. [1 ]
机构
[1] Univ Aquila, I-67100 Laquila, Italy
关键词
D O I
10.1016/j.transproceed.2010.03.066
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The objective of regenerative medicine (RM) and Tissue Engineering (TE) is to create living functional tissues to repair or replace tissues or organ functions. This field holds the promise of regenerating damaged tissues and organs in the body. It has the potential to solve the problems of organ shortage and of toxicities deriving from life-long immunosuppression. In fact, cells in the regenerated organ would match those of the patient, from whom they would normally be derived. In the past decade, RM/TE has achieved striking results which are of interest to the transplant community. However, major roadblocks on the avenue to full success include the need for a deeper understanding of cell biology and of interactions with the extracellular matrix. We are presently not able to grow and expand cells indefinitely and safely in various scenarios where RM/TE may be indicated. The production of adequately vascularized scaffolds to optimize nutrients and oxygen delivery, assessment of the viability and function of the cells in the bioengineered construct, and the costs remain areas of scientific research.
引用
收藏
页码:1011 / 1013
页数:3
相关论文
共 50 条
  • [21] Uterus transplantation: Where do we stand in 2018?
    Dion, L.
    Tardieu, A.
    Piver, P.
    Aubard, Y.
    Ayoubi, J. M.
    Garbin, O.
    Agostini, A.
    Collinet, P.
    Gauthier, T.
    Lavoue, V.
    JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION, 2019, 48 (01) : 11 - 13
  • [22] Islet transplantation: where do we stand now?
    Hirshberg, B
    Rother, KI
    Harlan, DM
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2003, 19 (03) : 175 - 178
  • [23] Biomarkers in kidney transplantation: Where do we stand?
    Lopez-Abad, A.
    Piana, A.
    Prudhomme, T.
    Marco, B. Banuelos
    Donmez, M. I.
    Pecoraro, A.
    Boissier, R.
    Campi, R.
    Breda, A.
    Territo, A.
    ACTAS UROLOGICAS ESPANOLAS, 2024, 48 (06): : 407 - 409
  • [24] Where do we stand on solid state microdosimetry?
    Zaider, M
    Dicello, JF
    Horowitz, Y
    RADIATION PROTECTION DOSIMETRY, 1999, 82 (03) : 163 - 166
  • [25] Human in vitro spermatogenesis as a regenerative therapy — where do we stand?
    Meghan Robinson
    Sydney Sparanese
    Luke Witherspoon
    Ryan Flannigan
    Nature Reviews Urology, 2023, 20 : 461 - 479
  • [26] Human in vitro spermatogenesis as a regenerative therapy - where do we stand?
    Robinson, Meghan
    Sparanese, Sydney
    Witherspoon, Luke
    Flannigan, Ryan
    NATURE REVIEWS UROLOGY, 2023, 20 (08) : 461 - 479
  • [27] Uterus transplantation:: where do we stand today and where should we go?
    Brannstrom, Mats
    Wranning, Caiza Almen
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (04) : 427 - 429
  • [28] Living donor liver transplantation: where do we stand and where are we going?
    Lu, Hao
    Lu, Ling
    Zhang, Feng
    Zhai, Yuan
    Wang, Xuehao
    HEPATOBILIARY SURGERY AND NUTRITION, 2016, 5 (02) : 141 - 144
  • [29] Regenerative medicine: where are we at?
    Thomas, R.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2009, 61 : A165 - A165
  • [30] PHARMACOGENOMICS OF ADME AND PERSONALIZED MEDICINE WHERE DO WE STAND?
    Schwab, Matthias
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S15 - S15